Mark J Rosenblum
CIK 1329154 · Exec VP Finance, CFO · last filed 2025-11-20
Mark J Rosenblum is an Exec VP Finance, CFO who has filed 32 SEC Form 4 insider transactions across 2 companies since 2013. The most recent filing shows the insider bought $16.0K of SLRX on Nov 20, 2025. Across all open-market trades the lifetime net is +$110.0K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
32
$110.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Exec VP Finance, CFO | 20,177 | $0.84 | $16.9K | $62.0K | 20 | 2025-11-20 |
| Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Chief Financial Officer | 113,774 | — | — | $48.0K | 4 | 2014-02-04 |
Recent Filings
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-11-20 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Buy (P) | +20,000 | $16.0K | EDGAR |
| 2024-02-22 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-02-15 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | +6,432 | $0 | EDGAR |
| 2023-01-05 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | +8,000 | $0 | EDGAR |
| 2022-12-12 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | +1,488 | $2.6K | EDGAR |
| 2022-11-08 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | +7,314 | $12.7K | EDGAR |
| 2022-11-07 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | +7,314 | $12.7K | EDGAR |
| 2022-05-31 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Buy (P) | +28,000 | $5.0K | EDGAR |
| 2022-05-05 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | +10,000 | $1.9K | EDGAR |
| 2022-03-09 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Buy (P) | +76,246 | $29.8K | EDGAR |